Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIXCYTE in knee osteoarthritis
NCT05526001Phase 3Active, not recruiting
- Sponsor
- UnicoCell Biomed Co., Ltd.
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing ELIXCYTE with Placebo (2 arms). Primary endpoint: Change of WOMAC Pain on the target knee at 24 weeks. Started Jul 2023; status: active, not recruiting.
02
Drugs
elixcyte
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05526001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526001.